DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
Oppenheimer - 2 Hartaj Singh - 2 Dado Ruvic - 1 Michael Yee - 1 Yee - 1 Manas Mishra - 1 Khushi - 1 Patrick Wingrove - 1
Top related locs:
United States US Boston Massachusets U.S Cambridge , Massachusetts Bengaluru New
Top related orgs:
Vertex Pharmaceuticals - 1 Pharmaceuticals - 1 CRISPR Therapeutics - 1 Food and Drug Administration - 1 REUTERS - 1 U.S - 1 Moderna - 1 Pfizer - 1

Search resuls for: "Hartaj Singh"


6 mentions found


☆ US FDA approves Vertex/CRISPR gene therapy for an inherited blood disorder
  + stars: | 2024-01-17 | by ( ) www.cnbc.com   time to read: +1 min
The headquarters of US biopharmaceutical company Vertex Pharmaceuticals in Boston, Massachusets, on November 4, 2023. The U.S. health regulator has approved Vertex Pharmaceuticals and CRISPR Therapeutics' gene therapy to treat a rare blood disorder requiring regular blood transfusions, in patients 12 years and older, Vertex said on Tuesday. The decision earns the therapy, branded as Casgevy, the second U.S. approval after it was greenlighted in December for sickle cell disease, another inherited blood disorder. The approval by the Food and Drug Administration comes more than two months ahead of its expected action date of March 30. Oppenheimer analyst Hartaj Singh said he expects a "slow and steady launch" for the therapy and estimated combined peak sales of about $400 million.
Persons: Oppenheimer, Hartaj Singh Organizations: Vertex Pharmaceuticals, Pharmaceuticals, CRISPR Therapeutics, Food and Drug Administration Locations: US, Boston, Massachusets, U.S, United States
☆ Unlike Pfizer, Moderna can meet 2023 COVID forecast, analysts say
  + stars: | 2023-11-01 | by ( Khushi Mandowara | ) www.reuters.com   time to read: +3 min
Syringes with needles are seen in front of a displayed Moderna logo in this illustration taken, November 27, 2021. Around 20 million people need to be vaccinated with Moderna's updated COVID-19 vaccine for the company to reach $2 billion in 2023 sales from the private market, a figure four analysts told Reuters was achievable. The company has said it expects total U.S. COVID vaccine demand to be as much as 100 million doses in the fall season. Moderna forecast $6 billion to $8 billion for sales of its COVID-19 vaccine in 2023, $2 billion to $4 billion of which is expected to come from the commercial market. The COVID vaccine is Cambridge, Massachusetts-based Moderna's lone marketed product.
Persons: Dado Ruvic, Oppenheimer, Hartaj Singh, Michael Yee, Yee, Manas Mishra, Khushi, Patrick Wingrove, Bill Berkrot Organizations: REUTERS, Reuters, U.S, Moderna, Pfizer, Jefferies, GSK, Thomson Locations: Cambridge , Massachusetts, United States, Bengaluru, New
☆ US FDA approves Pharming's immune disorder drug
  + stars: | 2023-03-24 | by ( Mariam Esunny Khushi Mandowara | Mariam Esunny | Khushi Mandowara | ) www.reuters.com   time to read: +2 min
March 24 (Reuters) - The U.S. Food and Drug Administration (FDA) on Friday approved Pharming Group's drug to treat a rare genetic disorder that leads to a weakened immune system, the Dutch company said. APDS causes a lack of functioning immune cells, B cells and T cells, which makes it difficult for people with this disorder to fight off bacterial and viral infections. At least two analysts expected the drug to be priced at as much as $400,000. Oppenheimer analyst Hartaj Singh expected Joenja to be priced between $250,000 and $400,000, and forecast peak sales of $200 million to $300 million, ahead of the approval. Joenja is an oral drug that targets and blocks a form of the protein called phosphoinositide 3-kinase delta (P13K).
☆ Drug companies face COVID cliff in 2023 as sales set to plummet
  + stars: | 2023-02-06 | by ( Michael Erman Patrick Wingrove | Michael Erman | Patrick Wingrove | ) www.reuters.com   time to read: +5 min
"When you think about traditional drug and vaccine development and longevity of sales, it's usually much more spread out," Morningstar analyst Damien Conover said. The sudden inflow of revenue should prod companies to strike deals and link up with new partners, he said. Vaccine maker Moderna also expects 2023 revenue to fall sharply. The company's only product - its messenger RNA COVID vaccine - pulled in around $18.4 billion in 2022. Eli Lilly and Co (LLY.N) made $2 billion in 2022 from monoclonal antibody COVID treatments and is not expecting any revenue from the business in 2023.
☆ Watch CNBC's full interview with Oppenheimer's Hartaj Singh
  + stars: | 2022-09-20 | by ( ) www.cnbc.com   time to read: 1 min
Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailWatch CNBC's full interview with Oppenheimer's Hartaj SinghHartaj Singh, Oppenheimer analyst, joins 'Squawk on the Street' to discuss how to play the biotech sector.
☆ You should probably keep owning Moderna or buy some, says Oppenheimer analyst
  + stars: | 2022-09-20 | by ( ) www.cnbc.com   time to read: 1 min
In this videoShare Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailYou should probably keep owning Moderna or buy some, says Oppenheimer analystHartaj Singh, Oppenheimer analyst, joins 'Squawk on the Street' to discuss how to play the biotech sector and more.
0 next >>
Total: 6